MedTrace Logo

Quality Assurance of Administering Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - QUMEA

NCT00730249 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2010-01-13

No results posted yet for this study

Summary

Investigation of efficacy of high-dose extended-release Methylphenidate in adults with ADHD, compared with a placebo

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

methylphenidate hydrochloride

sustained release, twice daily, dosage according to an individual titration schedule

DRUG

Placebo

twice daily according to an individual titration schedule

Sponsors & Collaborators

  • Medice Arzneimittel Pütter GmbH & Co KG

    lead INDUSTRY

Principal Investigators

  • Roland Fischer, Dr. · Medice Arzneimittel Pütter GmbH & Co KG

  • Michael Rösler, Prof. Dr. · Universität des Saarlandes, Institut für gerichtliche Psychiatrie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730249 on ClinicalTrials.gov